Law Firm Frank R. Cruz Announces Investigation into Globus Medical, Inc. (GMED) on Behalf of Investors

On August 13, 2024, the FDA issued a warning letter to Globus Medical regarding an inspection of the company’s Class II Excelsius GPS (EGPS) surgical robot. The FDA stated that the inspection revealed that “these devices are counterfeit” and do not meet regulatory requirements for quality systems.

On this news, Globus Medical’s stock price fell by $5.73, or 7.8%, to close at $67.32 per share on August 13, 2024. This was detrimental to investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Globus Medical securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email at [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email, please include your mailing address, telephone number and the number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under applicable law and ethical rules.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20240815984604/en/

The Globus Medical Registered (A) Stock at the time of publication of the news with a rise of +2.87 % to 62.75US dollar at the Lang & Schwarz stock exchange (August 15, 2024, 10:53 PM).